Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chronic Back Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chronic Back Pain - Pipeline Review, H2 2014', provides an overview of the Chronic Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Back Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Back Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Back Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Back Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chronic Back Pain Overview 7 Therapeutics Development 8 Pipeline Products for Chronic Back Pain - Overview 8 Pipeline Products for Chronic Back Pain - Comparative Analysis 9 Chronic Back Pain - Therapeutics under Development by Companies 10 Chronic Back Pain - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Chronic Back Pain - Products under Development by Companies 15 Chronic Back Pain - Companies Involved in Therapeutics Development 16 Astellas Pharma Inc. 16 Pfizer Inc. 17 Teva Pharmaceutical Industries Limited 18 Impax Laboratories, Inc. 19 Collegium Pharmaceutical, Inc. 20 Grunenthal GmbH 21 Endo Pharmaceuticals Inc. 22 Adynxx, Inc. 23 Chronic Back Pain - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 hydrocodone bitartrate ER - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 buprenorphine hydrochloride - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 oxycodone ER - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 (oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 bupivacaine Patch - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 cebranopadol - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ASP-7962 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 BCIBUBP-005 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 AYX-2 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Chronic Back Pain - Recent Pipeline Updates 48 Chronic Back Pain - Dormant Projects 57 Chronic Back Pain - Discontinued Products 58 Chronic Back Pain - Product Development Milestones 59 Featured News & Press Releases 59 May 01, 2014: ALO-02 Demonstrates Significant Difference In Pain Scores In Chronic Low Back Pain Patients And Lower Abuse Potential Compared To Immediate-Release Oxycodone In Recreational Opioid Users 59 Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin 60 Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform 61 Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program 62 Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 63 Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 63 Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 64 Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 64 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 67 Disclaimer 67
List of Tables Number of Products under Development for Chronic Back Pain, H2 2014 8 Number of Products under Development for Chronic Back Pain - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Chronic Back Pain - Pipeline by Astellas Pharma Inc., H2 2014 16 Chronic Back Pain - Pipeline by Pfizer Inc., H2 2014 17 Chronic Back Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 18 Chronic Back Pain - Pipeline by Impax Laboratories, Inc., H2 2014 19 Chronic Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 20 Chronic Back Pain - Pipeline by Grunenthal GmbH, H2 2014 21 Chronic Back Pain - Pipeline by Endo Pharmaceuticals Inc., H2 2014 22 Chronic Back Pain - Pipeline by Adynxx, Inc., H2 2014 23 Assessment by Monotherapy Products, H2 2014 24 Assessment by Combination Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Chronic Back Pain Therapeutics - Recent Pipeline Updates, H2 2014 48 Chronic Back Pain - Dormant Projects, H2 2014 57 Chronic Back Pain - Discontinued Products, H2 2014 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
